KR100884323B1 - 펩티드성 바소프레신 수용체 작용제 - Google Patents
펩티드성 바소프레신 수용체 작용제 Download PDFInfo
- Publication number
- KR100884323B1 KR100884323B1 KR1020067025140A KR20067025140A KR100884323B1 KR 100884323 B1 KR100884323 B1 KR 100884323B1 KR 1020067025140 A KR1020067025140 A KR 1020067025140A KR 20067025140 A KR20067025140 A KR 20067025140A KR 100884323 B1 KR100884323 B1 KR 100884323B1
- Authority
- KR
- South Korea
- Prior art keywords
- artificial sequence
- mod
- res
- compound
- group
- Prior art date
Links
- 0 CC*(C)(C)N[C@](*)C(***I)=O Chemical compound CC*(C)(C)N[C@](*)C(***I)=O 0.000 description 2
- RFNOOYBZJSWJGT-UHFFFAOYSA-N CCCS(NC(C)C(I)=O)[ClH]N Chemical compound CCCS(NC(C)C(I)=O)[ClH]N RFNOOYBZJSWJGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
치환기 Ar m n R2 p R3 | 서열번호 | |||||
Ph | 2 | 0 | H | 2 | H | 8 |
Ph | 3 | 0 | H | 3 | H | 9 |
Ph | 2 | 0 | OCH3 | 3 | H | 10 |
Ph | 3 | 0 | H | 2 | H | 11 |
4-피리딜 | 2 | 0 | H | 2 | H | 12 |
4-티아졸릴 | 2 | 0 | H | 2 | H | 13 |
2-티에닐 | 2 | 0 | H | 2 | H | 14 |
3-티에닐 | 2 | 0 | H | 2 | H | 15 |
Ph | 2 | 0 | OH | 3 | H | 16 |
2-티에닐 | 2 | 0 | H | 2 | H | 17 |
3-티에닐 | 2 | 0 | H | 2 | H | 18 |
Ph | 2 | 0 | CH3 | 3 | H | 19 |
Ph | 2 | 1 | CH3 | 3 | H | 20 |
Ph | 2 | 1 | CH(CH3)2 | 3 | H | 21 |
Ph | 3 | 0 | H | 3 | CH(CH3)2 | 1* |
Ph | 3 | 0 | H | 2 | CH(CH3)2 | 22 |
Ph | 1 | 2 | OH | 3 | H | 23 |
Ph | 1 | 0 | OH | 3 | H | 24 |
2-푸릴 | 2 | 0 | H | 3 | H | 25 |
Ph | 1 | 3 | OH | 3 | H | 2* |
2-푸릴 | 2 | 0 | H | 2 | H | 26 |
Ph | 1 | 0 | CH(CH2OH)2 | 3 | H | 27 |
Ph | 1 | 1 | CH(OH)CH3 | 3 | H | 28 |
Ph | 1 | 2 | OCH2CH2OH | 3 | H | 29 |
Ph | 1 | 0 | H | 3 | H | 30 |
Ph | 1 | 0 | H | 2 | H | 3* |
Ph | 1 | 0 | CH3 | 2 | H | 31 |
Ph | 1 | 1 | CH3 | 2 | H | 4* |
2-푸릴 | 2 | 0 | H | 3 | H | 32 |
2-티에닐 | 1 | 0 | H | 3 | H | 33 |
Ph | 2 | 0 | H | 3 | CH(CH3)2 | 5* |
2-티에닐 | 2 | 0 | H | 3 | CH(CH3)2 | 34 |
3-티에닐 | 1 | 0 | H | 3 | H | 35 |
2-티에닐 | 1 | 0 | H | 2 | H | 36 |
3-티에틸 | 1 | 0 | H | 2 | H | 37 |
2-푸릴 | 1 | 0 | H | 3 | H | 38 |
Ph | 2 | 0 | H | 3 | CH3 | 39 |
Ph | 2 | 0 | H | 3 | CH2CH2CH3 | 40 |
Ph | 1 | 0 | H | 3 | CH(CH3)2 | 41 |
2-푸릴 | 1 | 0 | H | 3 | CH(CH3)2 | 42 |
2-티에닐 | 1 | 0 | H | 3 | CH(CH3)2 | 43 |
2-푸릴 | 1 | 0 | H | 2 | H | 44 |
Ph | 2 | 0 | H | 3 | CH2CH3 | 6* |
Ph | 2 | 0 | H | 3 | (CH2)2CH(CH3)2 | 45 |
Ph | 1 | 0 | H | 3 | CH3 | 46 |
Ph | 1 | 0 | H | 3 | CH2CH3 | 47 |
Ph | 1 | 0 | CH3 | 3 | H | 7* |
Ph | 1 | 1 | CH3 | 3 | H | 48 |
Ph | 1 | 0 | CH3 | 3 | H | 49 |
Ph | 1 | 0 | H | 3 | CH2CH2CH3 | 50 |
Claims (12)
- 일반식(I)(서열번호 53)로 표시되는 화합물, 그것의 용매화물 및 그것의 약학적으로 허용가능한 염:상기 식에서,Ar은 페닐, 2-티에닐, 3-티에닐, 2-푸릴, 2-피리딜, 3-피리딜, 4-피리딜 및 4-티아졸릴로 이루어진 군으로부터 선택되고,m은 1, 2 및 3으로 이루어진 군으로부터 선택되며,n은 0, 1, 2, 3 및 4로 이루어진 군으로부터 선택되며,p는 2, 3 및 4로 이루어진 군으로부터 선택되며,R1, R2 및 R3은 독립적으로 H, OH, 알킬, O-알킬 및 OC(O)-알킬로 이루어진 군으로부터 선택되며,알킬은 C1-6 직쇄 알킬 및 C4-8 분지쇄 알킬로 이루어진 군으로부터 선택되며, 선택적으로 하나 이상의 하이드록실 치환체를 가지며,n이 0일 때, R1 및 R2는 선택적으로 함께 2 내지 5개의 탄소 원자를 포함하는 질소 함유 고리 구조를 형성하며,단, Ar이 페닐일 때, m=2, n=0 및 R1=R2=H이고, p가 3 또는 4일때 R3은 H가 아니다.
- 삭제
- 제 1항에 있어서, R1은 H인 것을 특징으로 하는 화합물.
- 제 1항에 있어서, p는 2 또는 3인 것을 특징으로 하는 화합물.
- 제 1항에 있어서, R2는 H, OH, CH3, CH2CH3, CH(CH3)2, CH(CH2OH)2, CH(OH)CH3, OCH3 및 OCH2CH2OH로 이루어진 군으로부터 선택되는 것을 특징으로 하는 화합물.
- 제 1항에 있어서, R3은 H, 메틸, 에틸, n-프로필, i-프로필 및 i-아밀로 이루어진 군으로부터 선택되는 것을 특징으로 하는 화합물.
- 제 1항, 또는 제 3항 내지 제 8항중 어느 한항에 있어서, 상기 화합물이 저혈량성 쇼크, 혈관이완성 쇼크, 또는 출혈성 식도 정맥류의 치료, 또는 심폐소생술을 위한 약제의 활성 성분으로서 사용되는 것을 특징으로 하는 화합물.
- 약학적으로 허용가능한 보강제, 희석제 또는 담체와 조합된 형태로 제 1항, 또는 제 3항 내지 제 8항중 어느 한항에 따른 화합물을 활성 성분으로서 포함하는, 저혈량성 쇼크, 혈관이완성 쇼크, 또는 출혈성 식도 정맥류의 치료, 또는 심폐소생술을 위한 약학적 조성물.
- 삭제
- 삭제
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60037704P | 2004-08-11 | 2004-08-11 | |
EP04019029 | 2004-08-11 | ||
EP04019029.0 | 2004-08-11 | ||
US60/600,377 | 2004-08-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070029183A KR20070029183A (ko) | 2007-03-13 |
KR100884323B1 true KR100884323B1 (ko) | 2009-02-18 |
Family
ID=34926126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067025140A KR100884323B1 (ko) | 2004-08-11 | 2005-08-03 | 펩티드성 바소프레신 수용체 작용제 |
Country Status (26)
Country | Link |
---|---|
US (2) | US8148319B2 (ko) |
EP (1) | EP1776133B1 (ko) |
JP (1) | JP4664363B2 (ko) |
KR (1) | KR100884323B1 (ko) |
CN (1) | CN1964732B (ko) |
AR (1) | AR050914A1 (ko) |
AT (1) | ATE509944T1 (ko) |
AU (1) | AU2005274070B2 (ko) |
BR (1) | BRPI0511466B8 (ko) |
CA (1) | CA2567797C (ko) |
DK (1) | DK1776133T3 (ko) |
ES (1) | ES2366702T3 (ko) |
HK (1) | HK1100280A1 (ko) |
IL (1) | IL178690A (ko) |
JO (1) | JO2937B1 (ko) |
MX (1) | MX2007001396A (ko) |
NO (1) | NO342449B1 (ko) |
NZ (1) | NZ550707A (ko) |
PL (1) | PL1776133T3 (ko) |
PT (1) | PT1776133E (ko) |
RU (1) | RU2355701C2 (ko) |
SA (1) | SA05260254B1 (ko) |
SI (1) | SI1776133T1 (ko) |
TW (1) | TWI364291B (ko) |
WO (1) | WO2006020491A1 (ko) |
ZA (1) | ZA200700772B (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2937B1 (en) * | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Tight muscles of the peptide vascular tensioner receptor |
CA2641959C (en) * | 2006-02-10 | 2016-12-20 | Ferring B.V. | Novel compounds |
ES2566143T3 (es) * | 2006-02-13 | 2016-04-11 | Ferring B.V. | Uso de agonistas peptídicos de receptor de vasopresina |
WO2009037586A2 (en) * | 2007-08-14 | 2009-03-26 | Ferring B.V. | Use of peptidic vasopressin receptor agonists |
EP2343982B1 (en) | 2008-09-17 | 2017-03-22 | Chiasma Inc. | Pharmaceutical compositions and related methods of delivery |
JO3109B1 (ar) * | 2012-05-10 | 2017-09-20 | Ferring Bv | منبهات لمستقبلات v1a |
US9388214B2 (en) | 2014-11-05 | 2016-07-12 | Ferring B.V. | V1A receptor agonists |
RU2634272C1 (ru) * | 2016-08-10 | 2017-10-24 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения |
MA46586A (fr) | 2016-10-21 | 2019-08-28 | Chiasma Inc | Compositions de terlipressine et leurs procédés d'utilisation |
US11033601B2 (en) | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
CN109748950B (zh) * | 2017-11-02 | 2020-10-30 | 深圳翰宇药业股份有限公司 | 一种固相合成血管升压素受体肽激动剂selepressin的方法 |
EP3517543B1 (en) * | 2018-01-30 | 2020-11-04 | Bachem AG | Manufacture of glucagon peptides |
JP2022507380A (ja) | 2018-11-15 | 2022-01-18 | フェリング ベスローテン フェンノートシャップ | 敗血症を治療するための化合物、組成物及び方法 |
WO2024073445A1 (en) * | 2022-09-30 | 2024-04-04 | Ocelot Bio, Inc. | Mixed vasopressin receptor agonist-antagonist for modulating mean arterial pressure |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459236A (en) * | 1990-02-27 | 1995-10-17 | Ferring Ab | Vasoactive vasotocin derivatives |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE651400A (ko) | 1963-04-05 | 1965-02-04 | ||
NL129421C (ko) * | 1963-08-30 | 1900-01-01 | ||
CS235151B1 (cs) | 1982-08-26 | 1985-05-15 | Michal Lebl | Způsob dělení Dal isomerů analogů oxytocinu |
US4829051A (en) | 1983-04-05 | 1989-05-09 | Vega Laboratories, Inc. | N-substituted derivatives of 1-desaminovasopressin |
US4483794A (en) | 1983-05-10 | 1984-11-20 | Ceskoslovenska Akademie Ved | Analogs of neurohypophysial hormones |
CS242062B1 (cs) | 1984-08-23 | 1986-04-17 | Milan Zaoral | Vasopresinová a vasotocinová analoga a způsob jejich přípravy |
SE457055B (sv) | 1986-08-18 | 1988-11-28 | Ferring Ab | Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser |
SE469473B (sv) | 1987-10-07 | 1993-07-12 | Ferring Ab | Vasoaktiva peptider |
RU2063979C1 (ru) | 1992-02-24 | 1996-07-20 | Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов | Пептиды последовательности окситоцина |
US5516795A (en) * | 1994-09-12 | 1996-05-14 | Abbott Laboratories | Heteroatom substituted propanyl derivatives having 5-lipoxygenase inhibitory activity |
GB9617021D0 (en) | 1996-08-13 | 1996-09-25 | Salpep Biotechnology Inc | Novel peptides for treatment of inflammation and shock |
SE9701161D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
SE9701162D0 (sv) | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
AU9484798A (en) | 1997-09-11 | 1999-03-29 | Public Health Research Institute Of The City Of New York, Inc., The | Enhancement of mucosal antibody responses by interleukin-6 |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
SE0001440D0 (sv) | 2000-04-18 | 2000-04-18 | Entretech Medical Ab | A drug against climacteric disorders |
WO2002064740A2 (en) | 2001-02-09 | 2002-08-22 | Cognetix, Inc. | Cone snail peptides |
AU2003220919A1 (en) * | 2002-03-29 | 2003-10-13 | Wakamoto Pharmaceutical Co., Ltd. | Drugs for increasing lacrimal fluid |
US6861236B2 (en) | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
ATE477811T1 (de) | 2002-10-03 | 2010-09-15 | Neuropharmacology Services Llc | Oxytocin zur behandlung von autismus und asperger-syndrom |
WO2004075783A2 (en) | 2003-02-26 | 2004-09-10 | Landry Donald W | A method for stabilizing blood pressure in hemodialysis subjects |
JO2937B1 (en) * | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Tight muscles of the peptide vascular tensioner receptor |
CA2641959C (en) * | 2006-02-10 | 2016-12-20 | Ferring B.V. | Novel compounds |
ES2566143T3 (es) * | 2006-02-13 | 2016-04-11 | Ferring B.V. | Uso de agonistas peptídicos de receptor de vasopresina |
JP2010513484A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
RU2342949C1 (ru) | 2007-03-26 | 2009-01-10 | Юрий Георгиевич Жуковский | Применение [дезамино-1, изолейцин-3, аргинин-8]вазопрессина в качестве средства для увеличения выведения почкой солей натрия и усиления обратного избирательного всасывания из почечных канальцев в кровь воды-растворителя |
-
2005
- 2005-07-17 JO JO2005102A patent/JO2937B1/en active
- 2005-07-19 TW TW094124322A patent/TWI364291B/zh not_active IP Right Cessation
- 2005-08-03 DK DK05783076.2T patent/DK1776133T3/da active
- 2005-08-03 BR BRPI0511466A patent/BRPI0511466B8/pt active IP Right Grant
- 2005-08-03 ES ES05783076T patent/ES2366702T3/es active Active
- 2005-08-03 MX MX2007001396A patent/MX2007001396A/es active IP Right Grant
- 2005-08-03 US US11/659,215 patent/US8148319B2/en active Active
- 2005-08-03 KR KR1020067025140A patent/KR100884323B1/ko active IP Right Grant
- 2005-08-03 SI SI200531312T patent/SI1776133T1/sl unknown
- 2005-08-03 RU RU2007101238/04A patent/RU2355701C2/ru active
- 2005-08-03 PL PL05783076T patent/PL1776133T3/pl unknown
- 2005-08-03 AT AT05783076T patent/ATE509944T1/de active
- 2005-08-03 AU AU2005274070A patent/AU2005274070B2/en active Active
- 2005-08-03 JP JP2007525670A patent/JP4664363B2/ja active Active
- 2005-08-03 EP EP05783076A patent/EP1776133B1/en active Active
- 2005-08-03 CA CA2567797A patent/CA2567797C/en active Active
- 2005-08-03 PT PT05783076T patent/PT1776133E/pt unknown
- 2005-08-03 CN CN2005800184358A patent/CN1964732B/zh active Active
- 2005-08-03 NZ NZ550707A patent/NZ550707A/en not_active IP Right Cessation
- 2005-08-03 WO PCT/US2005/027772 patent/WO2006020491A1/en active Application Filing
- 2005-08-11 AR ARP050103332A patent/AR050914A1/es unknown
- 2005-08-13 SA SA5260254A patent/SA05260254B1/ar unknown
-
2006
- 2006-10-17 IL IL178690A patent/IL178690A/en active IP Right Grant
-
2007
- 2007-01-26 ZA ZA200700772A patent/ZA200700772B/xx unknown
- 2007-03-12 NO NO20071314A patent/NO342449B1/no not_active IP Right Cessation
- 2007-08-01 HK HK07108387.7A patent/HK1100280A1/xx not_active IP Right Cessation
-
2012
- 2012-03-01 US US13/409,976 patent/US8778881B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459236A (en) * | 1990-02-27 | 1995-10-17 | Ferring Ab | Vasoactive vasotocin derivatives |
Non-Patent Citations (1)
Title |
---|
Lancet, 제359권, 제1209-1210면, 2002년. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100884323B1 (ko) | 펩티드성 바소프레신 수용체 작용제 | |
JP3405460B2 (ja) | ヘプタペプチドオキシトシン類似体 | |
EP1984012B1 (en) | Use of peptidic vasopressin receptor agonists | |
KR101194586B1 (ko) | 신규 화합물 | |
US9050286B2 (en) | Use of peptidic vasopression receptor agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130117 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140121 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150119 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180124 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20200203 Year of fee payment: 12 |